JPWO2020245133A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020245133A5 JPWO2020245133A5 JP2021571882A JP2021571882A JPWO2020245133A5 JP WO2020245133 A5 JPWO2020245133 A5 JP WO2020245133A5 JP 2021571882 A JP2021571882 A JP 2021571882A JP 2021571882 A JP2021571882 A JP 2021571882A JP WO2020245133 A5 JPWO2020245133 A5 JP WO2020245133A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- dimethyltryptamine
- enriched mixture
- pharmaceutically acceptable
- deuterated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 229910052805 deuterium Inorganic materials 0.000 claims 23
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 19
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- DMULVCHRPCFFGV-BNEYPBHNSA-N 1-deuterio-2-(1H-indol-3-yl)-N,N-dimethylethanamine Chemical compound [2H]C(Cc1c[nH]c2ccccc12)N(C)C DMULVCHRPCFFGV-BNEYPBHNSA-N 0.000 claims 4
- 150000001975 deuterium Chemical group 0.000 claims 4
- 125000004431 deuterium atom Chemical group 0.000 claims 4
- -1 deuterated N,N-dimethyltryptamine compound Chemical class 0.000 claims 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907871.6A GB201907871D0 (en) | 2019-06-03 | 2019-06-03 | Therapeutic compositions |
| GB1907871.6 | 2019-06-03 | ||
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022535093A JP2022535093A (ja) | 2022-08-04 |
| JP2022535093A5 JP2022535093A5 (https=) | 2023-05-30 |
| JPWO2020245133A5 true JPWO2020245133A5 (https=) | 2023-05-30 |
| JP7523474B2 JP7523474B2 (ja) | 2024-07-26 |
Family
ID=67385960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571882A Active JP7523474B2 (ja) | 2019-06-03 | 2020-06-02 | 重水素化された又は部分的に重水素化されたｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11771681B2 (https=) |
| EP (2) | EP3826632B1 (https=) |
| JP (1) | JP7523474B2 (https=) |
| KR (2) | KR20240142567A (https=) |
| CN (1) | CN114096246B (https=) |
| AU (1) | AU2020286709B2 (https=) |
| BR (1) | BR112021024333A2 (https=) |
| CA (2) | CA3142290C (https=) |
| DK (1) | DK3826632T3 (https=) |
| EA (1) | EA202193338A1 (https=) |
| ES (1) | ES2922101T3 (https=) |
| GB (4) | GB201907871D0 (https=) |
| HR (1) | HRP20220837T8 (https=) |
| HU (1) | HUE059439T2 (https=) |
| IL (1) | IL288617B2 (https=) |
| MX (1) | MX2021014728A (https=) |
| PL (1) | PL3826632T3 (https=) |
| PT (1) | PT3826632T (https=) |
| TW (1) | TWI860478B (https=) |
| WO (1) | WO2020245133A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) * | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| MX2022009528A (es) | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| AU2021204158B2 (en) * | 2020-06-02 | 2023-03-02 | Cybin Uk Ltd | Deuterated compounds |
| GB2605144A (en) * | 2021-03-22 | 2022-09-28 | Small Pharma Ltd | Deuterated compounds |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| WO2022043227A1 (en) * | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| IL303288A (en) | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| US20230136824A1 (en) | 2021-04-26 | 2023-05-04 | ATAI Life Sciences AG | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| MX2023012651A (es) * | 2021-04-26 | 2023-11-06 | Atai Therapeutics Inc | Novedosas composiciones y metodos de n,n-dimetiltriptamina. |
| IL308184A (en) * | 2021-05-05 | 2024-01-01 | Kare Chemical Tech Inc | Processes for the preparation of catalytic tryptamines and starting materials |
| JP2024522065A (ja) * | 2021-05-17 | 2024-06-11 | サイビン アイアールエル リミテッド | シロシビンの製剤 |
| IL308816A (en) * | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| EP4347559A4 (en) * | 2021-06-02 | 2025-04-09 | Saint Joseph's University | FLUORINATED TRYPTAMINE COMPOUNDS, RELATED ANALOGUES AND METHODS USING THEM |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| IL311050A (en) | 2021-08-23 | 2024-04-01 | Alexander Shulgin Res Institute Inc | Deuterated empathogens |
| IL311051A (en) * | 2021-08-23 | 2024-05-01 | Alexander Shulgin Res Institute Inc | Fluorinated empathogens |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| US20250002457A1 (en) * | 2021-10-29 | 2025-01-02 | Psilera Inc. | N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same |
| MX2024005955A (es) | 2021-11-18 | 2024-06-11 | Cybin Uk Ltd | Formulaciones inyectables e inhalables. |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023246690A1 (en) * | 2022-03-31 | 2024-11-07 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| EP4522167A1 (en) | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| AU2024242138A1 (en) | 2023-03-31 | 2025-11-13 | Cybin Uk Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| EP0593513B1 (en) | 1991-06-21 | 1998-10-28 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like receptors or 5-ht2 receptor agonistes |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| EP2036540A3 (en) | 2000-06-16 | 2009-12-16 | Jagotec AG | Improved injectable dispersions of propofol |
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| JP2010507585A (ja) | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換インドール |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| US20090093513A1 (en) | 2007-10-09 | 2009-04-09 | Hamann Mark T | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter |
| US20100069399A1 (en) * | 2008-09-15 | 2010-03-18 | Auspex Pharmaceutical, Inc. | Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| CN109251151A (zh) * | 2017-07-12 | 2019-01-22 | 北京广为医药科技有限公司 | N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途 |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| EP4353314A3 (en) | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| MD3927338T2 (ro) | 2019-02-22 | 2025-03-31 | Gh Res Ireland Limited | Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale |
| CN113784962B (zh) | 2019-02-27 | 2025-04-25 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| AU2020228289B2 (en) | 2019-02-27 | 2026-02-05 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN116056705A (zh) | 2020-08-05 | 2023-05-02 | 巴塞尔大学医院 | 用于dmt辅助心理疗法的静脉内dmt施用方法 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022043227A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| JP2023544724A (ja) | 2020-10-02 | 2023-10-25 | サイビン アイアールエル リミテッド | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| IL303288A (en) | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
-
2019
- 2019-06-03 GB GBGB1907871.6A patent/GB201907871D0/en not_active Ceased
-
2020
- 2020-06-02 EP EP20731372.7A patent/EP3826632B1/en active Active
- 2020-06-02 BR BR112021024333A patent/BR112021024333A2/pt unknown
- 2020-06-02 ES ES20731372T patent/ES2922101T3/es active Active
- 2020-06-02 HU HUE20731372A patent/HUE059439T2/hu unknown
- 2020-06-02 EA EA202193338A patent/EA202193338A1/ru unknown
- 2020-06-02 CN CN202080050439.9A patent/CN114096246B/zh active Active
- 2020-06-02 MX MX2021014728A patent/MX2021014728A/es unknown
- 2020-06-02 DK DK20731372.7T patent/DK3826632T3/da active
- 2020-06-02 PL PL20731372.7T patent/PL3826632T3/pl unknown
- 2020-06-02 WO PCT/EP2020/065244 patent/WO2020245133A1/en not_active Ceased
- 2020-06-02 US US16/890,664 patent/US11771681B2/en active Active
- 2020-06-02 GB GB2107702.9A patent/GB2592822B/en active Active
- 2020-06-02 CA CA3142290A patent/CA3142290C/en active Active
- 2020-06-02 IL IL288617A patent/IL288617B2/en unknown
- 2020-06-02 GB GB2100807.3A patent/GB2586940B/en active Active
- 2020-06-02 JP JP2021571882A patent/JP7523474B2/ja active Active
- 2020-06-02 GB GB2008303.6A patent/GB2585978B/en active Active
- 2020-06-02 KR KR1020247030292A patent/KR20240142567A/ko not_active Ceased
- 2020-06-02 HR HRP20220837TT patent/HRP20220837T8/hr unknown
- 2020-06-02 EP EP22173907.1A patent/EP4062910B1/en active Active
- 2020-06-02 US US17/616,345 patent/US12076311B2/en active Active
- 2020-06-02 PT PT207313727T patent/PT3826632T/pt unknown
- 2020-06-02 KR KR1020217043410A patent/KR20220034061A/ko not_active Ceased
- 2020-06-02 AU AU2020286709A patent/AU2020286709B2/en active Active
- 2020-12-23 CA CA3104072A patent/CA3104072C/en active Active
-
2021
- 2021-06-01 TW TW110119792A patent/TWI860478B/zh active
-
2024
- 2024-07-22 US US18/779,611 patent/US20240374565A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020245133A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| JP2018168191A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JPWO2021244831A5 (https=) | ||
| JP2009514874A5 (https=) | ||
| RU2005104418A (ru) | Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин | |
| JP2022108241A5 (https=) | ||
| JP2003503450A5 (https=) | ||
| JP2022153638A5 (https=) | ||
| JP2019516684A5 (https=) | ||
| JP2021505575A5 (https=) | ||
| IL273169B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| HRP20241345T1 (hr) | Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak | |
| JP2004526788A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2021505575A (ja) | 非ラセミ混合物およびその使用 | |
| CN110169962B (zh) | 用于治疗癌症的氧烯洛尔组合物 | |
| JP2011509301A5 (https=) | ||
| JP2021530554A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| CN103889409A (zh) | N-羟基-4-{2-[3-(n,n-二甲基氨基甲基)苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的给药方案 | |
| JP2020536048A5 (https=) | ||
| US20060270707A1 (en) | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus | |
| JPWO2018110669A5 (https=) |